Cirius Therapeutics
Mitochondrial-target metabolic therapeutics
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
AzemiglitazoneNo recent activity | Phase 2 | Mitochondrial pyruvate carrierSmall molecule | Type 2 Diabetes |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
4 November 2019Topline resultMSDC-0602K (azemiglitazone)Phase 2b EMMINENCE (NCT02784444) of MSDC-0602K in NASH missed its primary liver-histology endpoint
Global · Cirius Therapeutics · Source ↗
Financial reports
No financial reports recorded.